A Paleolithic diet confers higher insulin sensitivity, lower C-reactive protein and lower blood pressure than a cereal-based diet in domestic pigsAgrarian diet and diseases of affluence--do evolutionary novel dietary lectins cause leptin resistance?A paleolithic diet is more satiating per calorie than a mediterranean-like diet in individuals with ischemic heart diseaseIdentification, isolation, and characterization of daintain (allograft inflammatory factor 1), a macrophage polypeptide with effects on insulin secretion and abundantly present in the pancreas of prediabetic BB ratsBeneficial effects of a Paleolithic diet on cardiovascular risk factors in type 2 diabetes: a randomized cross-over pilot studyDPP-4 inhibition and islet functionG-protein-coupled receptors and islet function-implications for treatment of type 2 diabetes.The apj receptor is expressed in pancreatic islets and its ligand, apelin, inhibits insulin secretion in miceInhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetesCorrelation of apolipoprotein M with leptin and cholesterol in normal and obese subjectsA Palaeolithic diet improves glucose tolerance more than a Mediterranean-like diet in individuals with ischaemic heart diseaseNeonatal capsaicin-treatment in mice: effects on pancreatic peptidergic nerves and 2-deoxy-D-glucose-induced insulin and glucagon secretionGalanin-immunoreactive nerves in the mouse and rat pancreasImportant role of phosphodiesterase 3B for the stimulatory action of cAMP on pancreatic beta-cell exocytosis and release of insulinBeta-cell-targeted overexpression of phosphodiesterase 3B in mice causes impaired insulin secretion, glucose intolerance, and deranged islet morphologyRole of VIP and PACAP in islet function.The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes.Beta-cell-targeted expression of a dominant-negative mutant of hepatocyte nuclear factor-1alpha in mice: diabetes model with beta-cell dysfunction partially rescued by nonglucose secretagogues.Direct cytoplasmic CA(2+) responses to gastrin-releasing peptide in single beta cells.Effects of chemical sympathectomy by means of 6-hydroxydopamine on insulin secretion and islet morphology in alloxan-diabetic mice.Overweight is associated with lower serum leptin in Peruvian Indian than in Caucasian women: A dissociation contributing to low blood pressure?Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes.CART knock out mice have impaired insulin secretion and glucose intolerance, altered beta cell morphology and increased body weight.Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year.Beta-cell expression of a dominant-negative HNF-1alpha compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in mice.Insulin secretion after dietary supplementation with conjugated linoleic acids and n-3 polyunsaturated fatty acids in normal and insulin-resistant mice.Glucagon receptor antagonism improves islet function in mice with insulin resistance induced by a high-fat diet.Improved insulin sensitivity and islet function after PPARdelta activation in diabetic db/db mice.Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men.The canine sympathetic neuropeptide galanin: a neurotransmitter in pancreas, a neuromodulator in liver.Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy.Glucagon-like peptide-1 and glucose-dependent insulinotropic peptide: effects alone and in combination on insulin secretion and glucose disappearance in mice.Impact of glucose dosing regimens on modeling of glucose tolerance and β-cell function by intravenous glucose tolerance test in diet-induced obese mice.Islet amyloid and type 2 diabetes mellitus.Phospholipase A2 and its potential regulation of islet function.Stimulation of peripheral T3 formation by oral but not by intravenous glucose administration in fasted subjects.Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.The neuropeptide pituitary adenylate cyclase-activating polypeptide and islet function.Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes.Alpha 1- and alpha 2-adrenoceptor activation increases plasma glucagon levels in the mouse.
P50
Q21245074-77058A21-C24A-49F9-A9C1-BD00F90B5B55Q21256397-D1C69660-80EF-4B44-8D77-189ED6BC5A71Q24621806-63C6A846-1D75-4963-BCA4-DA0D173B349AQ24625957-F723E38C-E0CB-442A-9AA2-F5FAC38B5994Q24654138-87EF9930-F55B-4BEE-A634-E285831ABD4CQ27028127-9764B95E-D106-4BD7-B341-15EB98D57524Q27865197-140D769A-8D09-47FB-B362-7CF93DB19F99Q28257815-EC1E1AEC-1735-40C7-A620-4C78B5827FF4Q28260260-2BC2F937-FDD3-4885-89BA-4C24F93CC0E2Q28293086-ABD51821-EBDC-49E1-B3F9-A9426298E551Q28307231-F4BF2795-BBDC-4A6C-9C98-D46F3A183F9CQ28316273-05DBE506-6909-4DBC-9CFE-1ECC5757E848Q28324014-8ADB2BFD-2F5C-4A7E-B8C5-6F30B2478690Q28565526-528626EF-73B5-4761-905C-B14B3600231BQ28594896-25512B87-7F8F-4E06-BE45-1AAD478AC0E4Q30832022-8B46D970-3BDC-4600-8AF7-5BCBBE458DBFQ31131756-74B390FC-F655-479D-AA41-FF80991604A2Q31131767-04F7E616-FEC9-40AC-9F2A-F8D4A4D9CCDBQ31855529-EF0093A2-3477-493C-808F-C0DA53F03CF9Q32062812-854AC947-38D4-4007-9976-377C460668CDQ32076408-A40E846F-E8BF-4CDE-8324-FC6F24111CBEQ33209301-FD982C3D-2362-4C6A-ABA4-25345B1F81D6Q33216230-5E93E9BC-AB13-46C5-9FC2-F94BCC3F7952Q33220335-736A28C4-D652-4FE4-B7F9-1BCE71F2600EQ33223590-201A2307-A890-4B3A-9DCA-FF83B55578D8Q33224079-0F439C2D-3080-4F6F-87C8-5B6D2FDE67C6Q33283676-0A9FBE5A-3292-476E-BFA2-02BE1EC560C6Q33509686-FD3E388D-46C3-42E5-A456-69720F0D047BQ33518270-A5A0D91C-DFD7-48A8-8D48-E1390F703536Q33697322-78DA131F-C21A-4409-9D42-BAA77CC1BF70Q33751433-B12C80C7-B7FE-41D4-BA91-36234DCF1888Q33800196-56EF97DB-D269-42A1-B478-69DA0CBEEB16Q33902884-A35A8060-EE17-4A6A-99B5-810814947B06Q33912902-C7003DCC-546A-4247-9D21-3F52E783E66CQ33918661-DE4451B6-FD1B-4ACF-A600-D041EAF07C35Q34239151-745DB855-38EF-4293-B3E2-D96DF37CB22AQ34265490-BB7B4A0F-889B-44D2-8766-8A7A850BC314Q34346667-0D09EA74-9E35-4F07-9059-8DA97254D136Q34362258-71FAB5F8-5F80-45E5-BC20-1BC138A10C59Q34559941-30ADB706-89B5-41FA-BF00-757003DE2C63
P50
description
Zweeds arts
@nl
dokter asal Swedia
@id
hulumtues
@sq
médicu suecu
@ast
researcher
@en
schwedischer Arzt
@de
svensk läkare
@sv
taighdeoir
@ga
հետազոտող
@hy
طبيب سويدي
@ar
name
Bo Ahrén
@ast
Bo Ahrén
@ca
Bo Ahrén
@da
Bo Ahrén
@de
Bo Ahrén
@en
Bo Ahrén
@es
Bo Ahrén
@fi
Bo Ahrén
@fo
Bo Ahrén
@fr
Bo Ahrén
@ga
type
label
Bo Ahrén
@ast
Bo Ahrén
@ca
Bo Ahrén
@da
Bo Ahrén
@de
Bo Ahrén
@en
Bo Ahrén
@es
Bo Ahrén
@fi
Bo Ahrén
@fo
Bo Ahrén
@fr
Bo Ahrén
@ga
altLabel
Bo Ahren
@en
prefLabel
Bo Ahrén
@ast
Bo Ahrén
@ca
Bo Ahrén
@da
Bo Ahrén
@de
Bo Ahrén
@en
Bo Ahrén
@es
Bo Ahrén
@fi
Bo Ahrén
@fo
Bo Ahrén
@fr
Bo Ahrén
@ga
P106
P108
P21
P27
P31
P39
P569
1952-04-19T00:00:00Z